TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Trial Evaluating the Use of SR34006 in the Treatment of Deep Vein Thrombosis (DVT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Confirmed acute symptomatic DVT~* Written informed consent~Exclusion Criteria:~* Legal lower age limitations~* Patients with symptomatic pulmonary embolism~* Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of DVT~* Other indication for VKA than DVT~* More than 36 hours before the treatment with therapeutic dosages of low molecular weight heparin or initiation of VKA treatment prior to randomization~* Participation in another pharmacotherapeutic study within the prior 30 days~* Creatinine clearance \<10mL/min, severe hepatic disease or bacterial endocarditis~* Life expectancy \<3 Months~* Active bleeding or high risk for bleeding~* Uncontrolled hypertension: systolic blood pressure \>180 mm Hg and diastolic blood pressure \>110 mm Hg.~* Pregnancy or childbearing potential without proper contraceptive measures~* Any other contraindication listed in the labeling of warfarin, acenocoumarol, unfractionated heparin (UFH), enoxaparin, or tinzaparin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Therapy of Chronic Cold Agglutinin Disease With Eculizumab

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals at least 18 years of age~* Diagnosis of CAD defined by the combination of chronic hemolysis, cold agglutinin titer (IgM or IgA) \>64 at 4°C, positive direct antiglobulin test (DAT) when performed with polyspecific antiserum, negative (or only weakly positive) anti-IgG, and strongly positive with anti-C3d~* LDH level \> 2 x upper limit of normal (ULN)~* Clinical symptoms requiring treatment, such as anemia, anemia-related symptoms or hemolysis-related symptoms~* Sufficient supplementation of iron, folic acid and vitamin B12 prior to treatment phase~* Patient must be willing and able to give written informed consent;~* Patients must be vaccinated against N. meningitidis at least 14 days prior treatment~* Patient must avoid conception during the trial using a method that is most appropriate for their physical state and culture~Exclusion Criteria:~* Active aggressive lymphoma requiring therapy or an active non-lymphatic malignant disease other than basal cell carcinoma or CIS of the cervix~* Liver disease with elevated LDH~* Absolute neutrophil count \< 500/µL~* Presence or suspicion of active bacterial or viral infection, in the opinion of the Investigator, at treatment start or severe recurrent bacterial infections~* Participation in any other investigational drug trial or exposure to other investigational agent, device, or procedure within 30 days prior to screening period~* Pregnant, breast-feeding, or intending to conceive during the course of the study, including the Post-treatment Phase~* History of bone marrow/stem cell transplantation~* Inability to cooperate or any condition that, in the opinion of the investigator, could increase the patient's risk by participating in the study or confound the outcome of the study~* Hypersensitivity to eculizumab, to murine proteins or to one of the excipients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eculizumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Peri- And Postmenopausal Women With Major Depressive Disorder (DVS 3364)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Peri- and postmenopausal women aged 40 to 70 years who are fluent in both written and spoken English.~* Postmenopausal status defined by 12 consecutive months of spontaneous amenorrhea; less than 12 consecutive months with at least 6 consecutive months of spontaneous amenorrhea and a pre-baseline follicle-stimulating hormone (FSH) level \>40 mIU/mL; or 6 months postsurgical bilateral oophorectomy (with or without hysterectomy). Perimenopausal women defined by the presence of any of the following within 6 months before baseline:~  1. an absolute change of 7 days or more in menstrual cycle length within 6 months before baseline;~ 2. a change in menstrual flow amount (2 or more flow categories, eg, from light or moderately light to moderately heavy or heavy);~ 3. a change in duration (absolute change of 2 or more days); or~ 4. periods of amenorrhea lasting at least 3 months.~* A primary diagnosis of major depressive disorder (MDD) based on the criteria in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-Text Revision (DSM-IV-TR), single or recurrent episode, without psychotic features using the modified Mini International Neuropsychiatric Interview (MINI).~* A Montgomery and Asberg Depression Rating Scale (MADRS) total score \>=25 at the screening and baseline (day -1) visits and no more than a 5-point improvement from screening to baseline.~Exclusion Criteria:~* Treatment with DVS SR (Pristiq®) at any time in the past and/or venlafaxine, ie, Effexor® or Effexor XR®, 1 year prior to baseline.~* Treatment-resistant; eg, in the past 3 years if any of the following treatments have failed: (a) 3 or more previous adequate trials of \>=2 classes of antidepressant medication, (b) electroconvulsive therapy, or (c) 2 adequate trials of psychotherapy (eg, behavior therapy, behavior-marital therapy).~* History or current evidence of gastrointestinal disease known to interfere with the absorption or excretion of drugs or a history of surgery known to interfere with the absorption or excretion of drugs.~* Known presence of raised intraocular pressure or history of narrow-angle glaucoma.

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- desvenlafaxine succinate sustained-release (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: VR Intervention to Improve Police Safety

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females age 12 to 60 years.~* Documented autism spectrum disorder (ASD) diagnosis~* Verbal Intelligence Quotient (IQ) \>/= 75 (verbal and non-verbal)~* Informed consent (if adult) or parental/guardian permission (if child or adult with diminished capacity) and, if applicable, assent~Exclusion Criteria:~* Participation in pilot virtual reality (VR) study at the Children's Hospital of Philadelphia (CHOP)~* Personal or family history of seizures or a seizure disorder~* Primary sensory impairment (e.g., blindness, deafness)~* Personal or family history of migraines~* History of vertigo~* History of strabismus, other eye muscle problems, or eye surgery~* History of concussion with hospitalization~* Diagnosis of a known genetic syndrome (e.g., Down syndrome, Fragile X syndrome)~* History of a medical condition which has affected/affects cognitive, sensory, or motor functioning (e.g., Fetal Alcohol Syndrome, brain injury, stroke, brain tumor)~* Non-English speaking~* Parents/guardians or subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Phase IIA - in-person (Type: ACTIVE_COMPARATOR): Participants will be assigned to either a) a virtual reality-based intervention or b) an video modeling intervention both aimed at improving police interaction skills. Assessments of police skills will occur before intervention and after intervention (three sessions of each).
- Phase IIB - remote (Type: ACTIVE_COMPARATOR): Participants will be assigned to either a) three sessions of virtual reality-based intervention aimed at improving police interaction skills or b) no intervention. Assessments of police skills will occur before intervention, after intervention, and 3-4 weeks follow up in the intervention group and at comparable timepoints in the no intervention group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Olanzapine Compared to Lamotrigine in the Prevention of Depressive Episode in the Patients With Bipolar Disorder

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~The patients aged 15 to 50 who have bipolar disorder defined by the DSM-IV in remission state(YMRS\<12, HAMD\<7, CDR\<3) for at least two months and have already received olanzapine or lamotrigine as the maintenance treatment for one month. In addition, they should have at least three hypomanic, manic, depressive or mixed episodes previously.~Exclusion Criteria:~1. The patients are not willing to participate in the study after detailed explanation.~2. The patients who could not followed the investigators' instruction~3. The patients who have severe neurological or mental illness like epileptic disorder, history of stroke, schizophrenia, schizoaffective disorder, mental retardation or uncontrolled suicide risk.~4. The patients who have severe medical illness or surgical conditions like uncontrolled abnormal thyroid function, history of heart attack, uncontrolled hypertension.~5. The patient who are taking other mood stabilizers or antipsychotics within one month prior to the evaluation of entering our study.~6. The patients who are taking medications that might interfere with the metabolism of olanzapine or lamotrigine.~7. The patient who are allergy to olanzapine or lamotrigine.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- lamotrigine (Type: ACTIVE_COMPARATOR): maintenance treatment of the patients with bipolar disorder with olanzapine or lamotrigine
- olanzapine (Type: ACTIVE_COMPARATOR): maintenance treatment of the patients with bipolar disorder with olanzapine or lamotrigine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oxaliplatin in Treating Children With Advanced Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed metastatic or unresectable solid tumors that are not amenable to standard treatment~  * Histological confirmation not required for brain stem tumors~* No known brain metastases~* No leukemia~PATIENT CHARACTERISTICS:~Age:~* 21 and under~Performance status:~* ECOG 0-2 OR~* Lansky 50-100%~Life expectancy:~* Not specified~Hematopoietic:~* Absolute neutrophil count at least 1,000/mm\^3 (except with marrow involvement)~* Hemoglobin at least 8 g/dL~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin 0.2-1.4 mg/dL~* AST/ALT no greater than 3 times upper limit of normal~Renal:~* Creatinine normal for age OR~* Creatinine clearance at least 50 mL/min~* Electrolytes, calcium, and phosphorus normal~Cardiovascular:~* No symptomatic congestive heart failure, unstable angina, or cardiac arrhythmia~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception~* HIV negative~* No active graft-vs-host disease (GVHD)~* No allergy to platinum compounds or antiemetics~* No uncontrolled concurrent illness or infection~* No evidence of neuropathy~* Blood sugar normal~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 1 week since prior hematopoietic growth factors~* At least 3 months since prior stem cell transplantation and recovered~Chemotherapy:~* At least 3 weeks since prior chemotherapy (6 weeks for nitrosourea)~Endocrine therapy:~* Not specified~Radiotherapy:~* At least 6 weeks since prior extensive radiotherapy to significant marrow-containing compartment~* At least 6 months since prior craniospinal radiotherapy; total abdominal, pelvic, or extensive lung radiotherapy; or mantle and Y-port radiotherapy~* At least 6 months since prior total body irradiation~Surgery:~* Not specified~Other:~* No concurrent therapy for GVHD~* No other concurrent anticancer investigational or commercial agents~* No other concurrent anticancer therapy

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multi-Center, Double-Masked Evaluation of the Efficacy and Safety of CSF-1 in the Treatment of Presbyopia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must:~  1. Have presbyopia~Exclusion Criteria:~* Subjects must not:~  1. Have any contraindications to the study medications or diagnoses that would confound the study data

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- CSF-1 (Type: EXPERIMENTAL): This treatment arm consists of 2 different concentrations of CSF-1. Subjects randomized to the CSF-1 treatment arm will receive their first dose of CSF-1 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 arm will now receive a different concentration of CSF-1. Subjects will continue dosing twice a day in both eyes for approximately 1 week.
- CSF-1 Component #1 (Type: ACTIVE_COMPARATOR): This treatment arm consists of 2 different concentrations of CSF-1 Component #1.~Subjects randomized to the CSF-1 Component #1 treatment arm will receive their first dose of CSF-1 Component #1 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 Component #1 arm will now receive a different concentration of CSF-1 Component #1. Subjects will continue dosing twice a day in both eyes for approximately 1 week.
- CSF-1 Component #2 (Type: ACTIVE_COMPARATOR): This treatment arm consists of a single concentration of CSF-1 Component #2. Subjects randomized to the CSF-1 Component #2 treatment arm will receive their first dose of CSF-1 Component #2 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 Component #2 arm will continue dosing with the same concentration of CSF-1 Component #2. Subjects will continue dosing twice a day in both eyes for approximately 1 week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Cataract Surgery to Socioeconomic Status in Rural Area

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age-related cataract patients aged over 50 with best corrected visual acuity (BCVA) less than 0.3 in the better eye.~Exclusion Criteria:~* History of other eye disease that contributes to visual impairment, including keratopathy, uveitis, glaucoma, retinopathy, ocular trauma, or intraocular surgery.~* Cases in need of expedited surgery, including shallow anterior chamber (central anterior chamber depth less than 2 mm and/or peripheral anterior chamber depth less than 1/4 corneal thickness), blindness of grade IV and V (BCVA less than 0.02 in the better eye), and intumescent or hypermature stage of cortical cataract.~* Systemic disease dampening activity, including cardiovascular and cerebrovascular diseases, hemiplegia, neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.~* Patients not willing to participate in the study.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- waiting surgery (Type: PLACEBO_COMPARATOR): Cataract surgery will be performed at 1 year after enrollment.These participants will be provided with Phacolin eye drops(Zhongshan ophthalmic center, China).
- expedited surgery (Type: EXPERIMENTAL): Cataract surgery will be performed within 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Fistulizing Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with Crohn's disease of at least 3 months duration confirmed by radiography orendoscopy~* Having single or multiple draining enterocutaneous (including perianal) fistulae of at least 3 months duration~* If treated with oral prednisone (or equivalent), the dose must be \<=40 mg/day and must have been stable for at least 3 weeks prior to enrollment. (If currently not treated with oral prednisone, the stop date must have been at least 4 weeks prior to enrollment)~* If treated with 6-mercaptopurine or azathioprine, the start date must have been at least 6 months prior to enrollment. (The dose must have been stable for at least 8 weeks prior to enrollment. If currently not treated with 6-mercaptopurine or azathioprine, the stop date must have been at least 4 weeks prior to enrollment.)~Exclusion Criteria:~* Patients with local complications of Crohn's disease such as strictures or abscesses that might confound the evaluations of the benefit from cA2 treatment~* Having abscesses that should be drained prior to enrollment, with at least 3 weeks between drainage of the abscess and enrollment~* Having a serious infection, such as hepatitis, pneumonia or pyelonephritis, in the previous 3 months or a history of opportunistic infection such as herpes zoster within 2 months prior to screening, or evidence of active cytomegalovirus, active pneumocystis carinii, or drug resistant atypical mycobacterium~* Currently having signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic, endocrine, pulmonary, cardiac, neurologic or cerebral disease~* Currently having any known malignancy or any history of malignancy within the past 5 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Infliximab 10 mg/kg (Type: EXPERIMENTAL): Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 10 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2 and 6.
- Infliximab 5 mg/kg (Type: EXPERIMENTAL): Infliximab (anti-TNF chimeric monoclonal antibody \[cA2\]) 5 mg/kg will be administered as infusion at Week 0, 2 and 6.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo will be administered at Week 0, 2 and 6.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and/or Thinking Problems

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must meet research criteria for Parkinson's Disease with Dementia (PDD)~* Males and females, ages between 55 and 100~* Able to undergo psychometric testing~* Mini-Mental State Examination ≥ 21 and Clinical Dementia Rating \< 2~* Reliable informant with frequent contact with patient~Exclusion Criteria:~* Non-English speaking, as cognitive tests will be in English~* Evidence of other neurological or psychiatric disorders which preclude diagnosis of PDD (including, but not limited to, stroke, any psychotic disorder, severe bipolar or unipolar depression, seizure disorder, or head injury with loss of consciousness) within the past year~* Concurrent treatment with any acetylcholinesterase inhibitors (including rivastigmine in pill or patch form), antipsychotic agents (excluding quetiapine in dosages of 150 mg and lower, abilify and geodon as these medications are commonly used in treatment of Parkinson's Disease (PD) psychosis and should not affect results of study), mood stabilizers (valproate or lithium) or benzodiazepines (other than temazepam or zolpidem)~* Positive urine drug screen or suspected alcohol or substance abuse within last 1 year~* Current malignancy, or any clinically significant hematological, endocrine, cardiovascular, renal, hepatic, gastrointestinal or neurological disease. If the condition has been stable for at least the past year and is judged by the investigator not to interfere with the patient's participation in the study, the patient may be included~* Systolic blood pressure over 180 or less than 90 mm Hg. Diastolic blood pressure not greater than 105 or less than 50 mm Hg~* ECG is abnormal and judged to be clinically significant by the investigator~* Use of investigational drugs or participation in investigational drug studies within 30 days of screening~* Geriatric Depression Score score \> 15/30~* Hachinski score \> 4

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rivastigmine Patch 9.5 cm2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete